Group-Based Contingency Management for Substance Abuse Treatment - 1
2 other identifiers
interventional
312
1 country
1
Brief Summary
The purpose of this study is to evaluate the efficacy of prize-based contingency management (CM) when administered exclusively in groups. Substance dependent patients (N=360) at community-based treatment programs are randomly assigned to one of two conditions: (a) standard, non-CM treatment or (b) standard treatment plus prize CM delivered in groups. In the CM condition, patients earn the opportunity to win prizes for attending groups and submitting drug-free biological specimens. Substance use and psychosocial problems are measured at intake, month 1, month 3 (post treatment), and at 6-, 9-, and 12-month follow-up evaluations. We also assess patient characteristics that may be associated with improved outcomes within and across conditions.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for not_applicable
Started May 2005
Longer than P75 for not_applicable
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 1, 2005
CompletedFirst Submitted
Initial submission to the registry
November 3, 2005
CompletedFirst Posted
Study publicly available on registry
November 7, 2005
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2010
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2010
CompletedNovember 21, 2011
November 1, 2011
4.7 years
November 3, 2005
November 17, 2011
Conditions
Keywords
Outcome Measures
Primary Outcomes (2)
Drug use
baseline and at each follow-up
Retention
each follow-up
Interventions
Receive rewards (prizes) abstinence and attendance
Eligibility Criteria
You may qualify if:
- age \> 18 years
- current DSM-IV diagnosis of cocaine, opioid or alcohol abuse or dependence
- willing to provide breath and urine samples for 12 weeks
- English speaking
- willing to sign informed consent
You may not qualify if:
- serious, uncontrolled psychiatric illness (e.g., acute schizophrenia, bipolar disorder, severe or psychotic major depression, or suicide risk)
- dementia (\<23 on the Mini Mental State Exam; Folstein et al. 1975)
- in recovery from pathological gambling
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- UConn Healthlead
- National Institute on Drug Abuse (NIDA)collaborator
Study Sites (1)
University of Connecticut Health Center
Farmington, Connecticut, 06030, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Nancy Petry, Ph.D.
UConn Health
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
November 3, 2005
First Posted
November 7, 2005
Study Start
May 1, 2005
Primary Completion
January 1, 2010
Study Completion
January 1, 2010
Last Updated
November 21, 2011
Record last verified: 2011-11